JP2020530120A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530120A5
JP2020530120A5 JP2020507022A JP2020507022A JP2020530120A5 JP 2020530120 A5 JP2020530120 A5 JP 2020530120A5 JP 2020507022 A JP2020507022 A JP 2020507022A JP 2020507022 A JP2020507022 A JP 2020507022A JP 2020530120 A5 JP2020530120 A5 JP 2020530120A5
Authority
JP
Japan
Prior art keywords
biomarker
subject
heart failure
biological sample
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020507022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530120A (ja
JP7414281B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2018/050827 external-priority patent/WO2019028507A1/en
Publication of JP2020530120A publication Critical patent/JP2020530120A/ja
Publication of JP2020530120A5 publication Critical patent/JP2020530120A5/ja
Application granted granted Critical
Publication of JP7414281B2 publication Critical patent/JP7414281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020507022A 2017-08-08 2018-08-08 初期心不全の診断方法 Active JP7414281B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017903138A AU2017903138A0 (en) 2017-08-08 Methods for Diagnosis of Early Stage Heart Failure
AU2017903138 2017-08-08
PCT/AU2018/050827 WO2019028507A1 (en) 2017-08-08 2018-08-08 METHODS OF DIAGNOSING PRECOCUS STAGES OF CARDIAC INSUFFICIENCY

Publications (3)

Publication Number Publication Date
JP2020530120A JP2020530120A (ja) 2020-10-15
JP2020530120A5 true JP2020530120A5 (enExample) 2021-09-16
JP7414281B2 JP7414281B2 (ja) 2024-01-16

Family

ID=65273054

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020507022A Active JP7414281B2 (ja) 2017-08-08 2018-08-08 初期心不全の診断方法

Country Status (6)

Country Link
US (1) US20200174021A1 (enExample)
EP (1) EP3665483A4 (enExample)
JP (1) JP7414281B2 (enExample)
CN (1) CN111465857A (enExample)
AU (2) AU2018315056B2 (enExample)
WO (1) WO2019028507A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021283390A1 (en) 2020-06-03 2023-01-19 Esn Cleer Biomarker identification for imminent and/or impending heart failure
CN115327129A (zh) * 2022-07-05 2022-11-11 上海交通大学医学院附属上海儿童医学中心 一种血浆分子标志物犬尿氨酸在早期心力衰竭检测中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094870A2 (en) * 2000-11-02 2002-11-28 Curagen Corporation Proteins and nucleic acids encoding same
US20030113726A1 (en) * 2000-12-04 2003-06-19 Zenta Tsuchihashi Human single nucleotide polymorphisms
US20040033582A1 (en) * 2002-06-03 2004-02-19 Manling-Ma Edmonds Human single nucleotide polymorphisms
TW200413539A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Genes and polypeptides relating to prostate cancers
JP2005110602A (ja) 2003-10-09 2005-04-28 Sumitomo Pharmaceut Co Ltd アトピー性皮膚炎の疾患マーカー及びその利用
WO2006008002A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with kallikrein 1 (klk1)
WO2006015209A2 (en) * 2004-07-29 2006-02-09 Stem Cell Innovations, Inc. Differentiation of stem cells
EP1722232A1 (en) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Devices and methods for diagnosing or predicting early stage cardiac dysfunctions
WO2007047995A2 (en) * 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
JP2009541287A (ja) * 2006-06-20 2009-11-26 リポペプチド・アクチエボラーグ 抗癌剤としてのカテリシジン抗菌タンパク質（ｈＣＡＰ１８）の使用
WO2008000067A1 (en) * 2006-06-26 2008-01-03 Vasogen Ireland Limited Treatment of mild chronic heart failure in human patients
CA2791144C (en) * 2006-07-05 2019-04-09 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
DK2046951T5 (da) * 2006-07-05 2012-01-23 Catalyst Biosciences Inc Proteasesreeningsmetoder og proteaser identificeret dermed
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
US20100267052A1 (en) * 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
CA2671267A1 (en) * 2006-11-30 2008-06-05 Navigenics Inc. Genetic analysis systems and methods
ZA200903761B (en) * 2006-11-30 2010-08-25 Navigenics Inc Genetic analysis systems and methods
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
WO2011133770A2 (en) * 2010-04-21 2011-10-27 Board Of Regents Of The University Of Texas System Salivary protein markers for detection of breast cancer
EP2671083A1 (en) * 2011-02-03 2013-12-11 Abbott Laboratories Methods of prognosis and diagnosis in chronic heart failure
US20150045245A1 (en) * 2011-12-08 2015-02-12 Biocartis Nv Biomarkers and test panels useful in systemic inflammatory conditions
WO2013090811A1 (en) * 2011-12-14 2013-06-20 The Johns Hopkins University Biomarkers of pulmonary hypertension
US10131709B2 (en) * 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
EP2877213B1 (en) * 2012-07-25 2020-12-02 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
EP2885637B1 (en) 2012-08-15 2016-11-30 The Procter & Gamble Company Use of human ex vivo skin model in a method of identifying modulators of skin inflammation
WO2014193999A2 (en) * 2013-05-28 2014-12-04 Caris Science, Inc. Biomarker methods and compositions
CN104049082B (zh) * 2014-05-30 2016-03-16 华中科技大学同济医学院附属同济医院 人组织激肽释放酶活性检测试剂盒及其应用
CN105987998B (zh) * 2015-01-30 2017-12-29 江苏众红生物工程创药研究院有限公司 人组织激肽释放酶1elisa定量检测试剂盒
EP3259594A4 (en) * 2015-02-20 2018-12-26 The Johns Hopkins University Biomarkers of myocardial injury

Similar Documents

Publication Publication Date Title
Ashton et al. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
Vos et al. Variability of CSF Alzheimer’s disease biomarkers: implications for clinical practice
Abe et al. Liver dysfunction assessed by model for end-stage liver disease excluding INR (MELD-XI) scoring system predicts adverse prognosis in heart failure
Mirza et al. The N-terminal pro B-type natriuretic peptide, and risk of dementia and cognitive decline: a 10-year follow-up study in the general population
CN109844532B (zh) 分析生物数据的系统和方法
Ljungberg et al. Proteomic biomarkers for incident aortic stenosis requiring valvular replacement
Agnello et al. Establishing the upper reference limit of Galectin-3 in healthy blood donors
JP2019509068A5 (enExample)
Reque et al. Pulmonary hypertension is an independent predictor of cardiovascular events and mortality in haemodialysis patients
Park et al. The 2016 ASE/EACVI recommendations may be able to more accurately identify patients at risk for diastolic dysfunction in living donor liver transplantation
Artunc et al. Plasma concentrations of the vasoactive peptide fragments mid-regional pro-adrenomedullin, C-terminal pro-endothelin 1 and copeptin in hemodialysis patients: associated factors and prediction of mortality
JPWO2018008763A1 (ja) アルツハイマー型認知症の将来の発症リスクの評価方法
Trifa et al. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia
JP2020530120A5 (enExample)
Schenck et al. Enlarged pulmonary artery is predicted by vascular injury biomarkers and is associated with WTC-Lung Injury in exposed fire fighters: a case–control study
JP2016526167A5 (enExample)
Kuusela et al. Changes in plasma protein levels as an early indication of a bloodstream infection
Papaioannou et al. Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)
Libby et al. Whole blood transcript and protein abundance of the vascular endothelial growth factor family relate to cognitive performance
Chen et al. C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations
Vigil et al. Predictors of a rapid decline of renal function in patients with chronic kidney disease referred to a nephrology outpatient clinic: a longitudinal study
Hartman et al. Proenkephalin as a new biomarker for pediatric acute kidney injury–reference values and performance in children under one year of age
JP2015505371A5 (enExample)
Canney et al. Glomerular filtration rate-specific cutoffs can refine the prognostic value of circulating cardiac biomarkers in advanced chronic kidney disease
Ko et al. Undiagnosed airflow limitation is common in patients with coronary artery disease and associated with cardiac stress